Landmark legislation in Italy: Provisions for the treatment of rare diseases and for the support of research and production of orphan drugs
FDA approves first drug to improve growth in children with most common form of Dwarfism
NICE creates new menu of treatment options for those suffering from depression
We examine the effects on patient access, specifically regarding pathways, high value steps, multi-i...
Our analysts explore NICE's integration of tech appraisals into treatment guidelines for to enable o...
Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.
Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.